Episode 6 – mAbs and SARS-CoV-2 with Dr Carter Mitchell & Dr Sharath Madasu, Kemp Proteins
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
In this episode of Drug Target Review’s podcast, in association with Molecular Devices, Editor Victoria Rees speaks with Dr Carter Mitchell, Chief Science Officer at Kemp Proteins and Dr Sharath Madasu, Manager of Protein Characterisation at Kemp Proteins about the use of monoclonal antibodies (mAbs) against SARS-CoV-2.
The speakers explain why mAbs are a useful tool against SARS-CoV-2 and how they work to neutralise the virus. The ways in which mAb development workflows have recently evolved is also explored, including in response to emerging SARS-CoV-2 variants.
Key discussion points:
- The mechanism of action of SARS-CoV-2-neutralising mAbs
- The advantages of mAbs over convalescent plasma therapy
- How the pandemic has advanced and accelerated the development of mAbs
- Where the biggest challenges and bottlenecks lie for mAb development
- How to accelerate mAb discovery and development and the role of automation
- What the future of SARS-CoV-2 treatment will look like.
Make sure you don’t miss out on any podcasts from Drug Target Review – sign up here to be notified of new podcast releases!
Dr Carter Mitchell is Chief Scientific Officer of Kemp Proteins. He earned a PhD in Structural Biology and prior to joining Kemp Proteins, he was the Chief Technology Officer and Director of Structural Biology at a biotech start-up where he built, developed and implemented protein expression and isolation laboratory and managed the protein production and purification team. Currently, he is streamlining operations and implementing high-throughput expression and purification strategies for antigens, multispecific antibodies and Virus-Like Particles.
Dr Sharath Madasu leads the Protein Characterisation team at Kemp Proteins. He earned a PhD in Cell Molecular and Biomedical Sciences, where he identified novel protein interactors involved in the regulation of potassium channels – Kv1.2 in the mammalian brain. Prior to joining Kemp Proteins, he was a Senior Scientist at a biotech start-up where he built and led an antibody team and oversaw the initial assay development and affinity characterisation work to select lead antibody candidates for a pre-clinical pipeline.